Automated insulin delivery was improved with improved glycemic control metrics among patients with type 2 diabetes regardless of C-peptide levels.
Continuous glucose monitoring can identify unrecognized hyperglycemia and hypoglycemia in dialysis patients, challenging ...
In a report released today, Suraj Kalia from Oppenheimer maintained a Hold rating on Dexcom. The company’s shares closed yesterday at $68.20. Take advantage of TipRanks Premium at 50% off! Unlock ...
Hosted on MSN
Why DexCom Stock Is Crashing Today
DexCom beat expectations in the third quarter, and it raised its revenue guidance for the full year. Manufacturing issues are putting pressure on margins. For 2026, the company sees growth missing ...
RBC Capital lowered the firm’s price target on DexCom (DXCM) to $85 from $100 but keeps an Outperform rating on the shares. The market misunderstood the conservative initial 2026 guide, which likely ...
As of October 30, 2025, the average one-year price target for DexCom is $102.13/share. The forecasts range from a low of $85.07 to a high of $126.00. The average price target represents an increase of ...
The accompanying press release dated October 30, 2025 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating ...
InvestingPro analysis reveals that DexCom maintains a healthy current ratio of 1.52 and operates with moderate debt levels, suggesting strong operational stability. DexCom faces what Piper Sandler ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback